CIMA University of Navarra at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
CIMA University of Navarra brings 23 presentations to ESGCT 2026 in Hamburg. Its program centres on CAR T cell engineering for solid tumours and on AAV vectors for liver, kidney and inner ear targets. One strand examines immune responses and liver toxicity after AAV dosing, alongside oncolytic adenovirus work in recurrent glioblastoma.
| Organization | ESGCT 2026 Attendance |
|---|---|
CIMA University of Navarra Pamplona, Spain | |
University of Navarra's applied medical research centre, with gene therapy programs on viral vectors for liver, rare and neurodegenerative diseases. | Chair Tue Oct 27 9:00am–10:45am EDUCATION SESSION 1b - Therapeutic strategies expanding the horizons of GT Cell therapies and CAR-TGene and epigenome editing Workshop Tue Oct 27 11:40am–1:00pm Side effects and protein stress response Clinical trials and translation Chair Tue Oct 27 5:00pm–7:30pm SESSION 2d: Metabolic diseases I In collaboration with JSGCT and CSGCT Rare and inherited disease Talk Tue Oct 27 6:00pm–7:30pm Molecular mechanism of severe hepatotoxicity following high-dose ssAAV9.CBA.SMN1 administration in neonatal mice Vectors and delivery (AAV, lentiviral, LNP)Rare and inherited disease Chair Wed Oct 28 8:30am–10:30am SESSION 3a: AAVs/non integrative vectors II - Technology Vectors and delivery (AAV, lentiviral, LNP) Talk Wed Oct 28 9:30am–10:30am Preliminary results of a phase I trial evaluating DNX-2440 oncolytic adenovirus in recurrent glioblastoma Cancer gene and cell therapyClinical trials and translation Talk Wed Oct 28 12:00pm–12:30pm Poster Wed Oct 28 1:30pm–3:30pm Cross-species AAV capsid screening identifies non-sensory cochlear vectors for GJB2-related hearing loss gene therapy Poster Wed Oct 28 1:30pm–3:30pm Distinguishing real AAV-mediated renal transduction from proximal tubule protein reabsorption: implications for the assessment of renal gene therapy Poster Wed Oct 28 1:30pm–3:30pm Framework-region charge optimization enhances the anti-tumor potency of CAR-T cells across multiple solid tumors by calibrating tonic signal Poster Wed Oct 28 1:30pm–3:30pm Impact of Radiotherapy on Tumor—CAR-T Cell Interaction Poster Wed Oct 28 1:30pm–3:30pm NKG7 and CMC1 as key mediators underlying clonal expansions in BCMA CAR-T cells Poster Wed Oct 28 1:30pm–3:30pm Rapid and dynamic reprogramming within the tumor microenvironment drives EDA-CAR-T dysfunction and compromised therapeutic efficacy in solid tumors Poster Wed Oct 28 1:30pm–3:30pm Rational design of immunomodulatory peptide display strategies for inducing anti-AAV immune tolerance Poster Wed Oct 28 1:30pm–3:30pm Rational engineering of sdAb-based CAR T cells targeting BCMA enhances antitumor efficacy and persistence in Multiple Myeloma Poster Wed Oct 28 1:30pm–3:30pm Retroureteral delivery of engineered AAV capsids drives robust and widespread renal epithelial transduction Chair Wed Oct 28 3:30pm–5:30pm SESSION 5: In vivo gene therapy Vectors and delivery (AAV, lentiviral, LNP) Talk Thu Oct 29 9:00am–10:30am Leveraging immune recognition for developing safer and more potent AAV-based gene therapies Vectors and delivery (AAV, lentiviral, LNP) Poster Thu Oct 29 2:00pm–4:00pm A synergistic neurohepatic promoter enables single-AAV correction of mitochondrial function in COXPD1 Poster Thu Oct 29 2:00pm–4:00pm Beyond Sensitivity: Intermediate Functional Avidity Drives Superior In Vivo Antitumor Efficacy in TCR-Engineered T Cells Poster Thu Oct 29 2:00pm–4:00pm Generation and characterization of BCMA-targeting humanized scFv-based CAR-T cells for multiple myeloma Poster Thu Oct 29 2:00pm–4:00pm Inhibiting DNA-PK minimizes unwanted rAAV integration during CRISPR-Cas9 editing in vivo Poster Thu Oct 29 2:00pm–4:00pm Novel HER2-Specific sdAb-CAR-T Cells Exhibit Enhanced Antitumoral Efficacy in HER2-Positive Cancers Poster Thu Oct 29 2:00pm–4:00pm Single-cell multiomic profiling defines molecular signatures of human long-term hematopoietic stem cells for next generation gene therapy applications Cell therapies and CAR-T Poster Thu Oct 29 2:00pm–4:00pm Type I interferon-driven mechanisms underlying the therapeutic synergy of CAR-T cells and Semliki Forest virus-based companion vaccines for solid tumor therapy Poster Thu Oct 29 2:00pm–4:00pm Uncovering key regulators of CAR-T cell senescence via immune phenotyping and integrated CRISPR screens Chair Thu Oct 29 6:30pm–7:30pm SESSION 10: Enabling technologies Manufacturing, CMC and access Talk Fri Oct 30 12:45pm–1:00pm Comparative study of viral and non-viral delivery systems for cytokine-expressing self-amplifying RNA in cancer therapy RNA and oligonucleotide therapiesCancer gene and cell therapy |
Instantly find 20 buyers from CIMA University of Navarra
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction